Phase II drugs that are currently in development for the treatment of cachexia
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Cachexia is a syndrome presenting with progressive unintentional weight loss and wasting and weakness of skeletal muscle. Cachexia is prevalent in cancer and in chronic diseases including chronic obstructive pulmonary disease (COPD). AREAS COVERED: The authors searched trial registers for current Phase II clinical trials on cachexia. Twelve studies were found with 11 compounds, including the anti-inflammatory drugs thalidomide, OHR/AVR118, celecoxib, VT-122, omega-3 supplements, and anabolic agents such as ghrelin analogues, MT-102, BYM338 and ruxolotinib. The authors note that one of the studies related to COPD while the others were related to different cancers. Herein, the authors describe the mechanisms of action and their Phase II study design. EXPERT OPINION: The compounds under study affect several pathways involved in cachexia by modulating inflammatory activity, anabolic potential, digestion and direct interaction with the muscle. Due to the multifactorial aspects of cachexia syndrome, combinations of these new drugs with nutritional intervention is probably the most promising approach. Furthermore, future studies should include interventions in pre-cachetic patients, as this stage might be more responsive to treatment. Future studies will benefit from well-defined end points and improved measures of cachexia, providing new insight into the disease. This insight, in combination with the elucidation of cachexia's underlying mechanism, will yield new treatment strategies in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · cited 1×
“03 kg) [84].”
IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Hasselgren, P.-O., Frontera, W. R., Lee, J., Glass, D. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.027 · Cited by 1,367
Increased mortality associated with growth hormone treatment in critically ill adults
Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., & Hinds, C. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411102 · Cited by 1,023
Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome
Sandri, M. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.04.023 · Cited by 689 · cited 1×
“Several mechanisms underlying the net muscle protein loss in cachexia have been proposed as comprehensively reviewed recently in a special issue of the International Journal of Biochemistry and Cell Biology [8-11].”
Smith, G. I., Atherton, P., Reeds, D. N., Mohammed, B. S., Rankin, D., Rennie, M. J., & Mittendorfer, B. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.005611 · Cited by 665
Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., Koniaris, L. G., & Zimmers, T. A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2012 · Cited by 463 · cited 1×
“Importantly, an IL-6 STAT signaling axis has been implicated in muscle wasting in an experimental model of cancer cachexia [82], supporting a potential for modulation of JAK/ STAT signaling to treat cachexia.”
Bonetto, A., Aydogdu, T., Kunzevitzky, N., Guttridge, D. C., Khuri, S., Koniaris, L. G., & Zimmers, T. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022538 · Cited by 348 · cited 1×
“It inhibits the production of proinflammatory cytokines as TNF-a and IL-6, which have been implicated as triggers of cachexia through activation of NF-kB [19,20] and STAT3 [41] signaling.”
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 1×
“In mouse models, it has been shown that BYM338 inhibits myostatin and the activin signaling in skeletal myoblasts and myotubes [79].”
Muscle Atrophy and Hypertrophy Signaling in Patients with Chronic Obstructive Pulmonary Disease
Doucet, M., Russell, A. P., Léger, B., Debigaré, R., Joanisse, D. R., Caron, M.-A., LeBlanc, P., & Maltais, F. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-704oc · Cited by 243 · cited 19×
“Several studies are ongoing with BYM338 in different patient populations: COPD, cancer and patients who are mechanically ventilated.”
Influential
Cited by
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574
“Other compounds under investigation as treatments for sarcopenia include myostatin, vitamin D, angiotensin-converting enzyme inhibitors, eicosapentaenoic acid,(30,31) thalidomide, OHR/AVR118, celecoxib, VT-122, omega-3 supplements, and anabolic agents such as ghrelin and its analogues, MT-102, BYM338, and ruxolotinib.…”
Backgroundvan Vugt, J. L. A., Levolger, S., de Bruin, R. W. F., van Rosmalen, J., Metselaar, H. J., & IJzermans, J. N. M. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13732 · Cited by 361
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
Levolger, S., van Vugt, J. L. A., de Bruin, R. W. F., & IJzermans, J. N. M. (2015) · British Journal of Surgery · doi:10.1002/bjs.9893 · Cited by 270
Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90
Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H. A., Sin, K. W. T., Zhu, Z. J., Flores, R., Wen, Y., Gong, X., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00726-x · Cited by 248
Metadata
- Authors
- Dingemans, A.-M. C., de Vos-Geelen, J., Langen, R., & Schols, A. M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2014-07-24
- Volume
- 23
- Issue
- 12
- Pages
- 1655-1669
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2061496437
- Cited by
- 41
- References
- 14
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II drugs that are currently in development for the treatment of cachexia. https://app.cochat.ai/papers/10.1517/13543784.2014.942729
- The paper
- Dingemans, A.-M. C., de Vos-Geelen, J., Langen, R., & Schols, A. M. (2014). Phase II drugs that are currently in development for the treatment of cachexia. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2014.942729
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.